Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Consensus Rating of "Buy" from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) has been given an average recommendation of "Buy" by the seven ratings firms that are covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $25.83.

Several equities analysts have weighed in on the company. Guggenheim reaffirmed a "buy" rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating on the stock.

Centessa Pharmaceuticals Stock Down 1.7 %

Shares of CNTA stock traded down $0.28 on Friday, reaching $15.98. 680,312 shares of the company's stock traded hands, compared to its average volume of 782,807. The business's 50 day moving average price is $16.74 and its two-hundred day moving average price is $15.78. The company has a market capitalization of $2.11 billion, a P/E ratio of -10.44 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals has a 12-month low of $7.75 and a 12-month high of $19.09.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 1,671 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $18.24, for a total transaction of $30,479.04. Following the transaction, the chief executive officer now directly owns 575,661 shares of the company's stock, valued at $10,500,056.64. This represents a 0.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the firm's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $17.66, for a total value of $176,600.00. Following the transaction, the insider now owns 183,266 shares in the company, valued at approximately $3,236,477.56. This trade represents a 5.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 397,652 shares of company stock worth $6,871,582 in the last 90 days. 11.59% of the stock is owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter worth $31,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock worth $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC boosted its stake in Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after purchasing an additional 865 shares during the period. Barclays PLC grew its holdings in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after buying an additional 4,952 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at approximately $162,000. Institutional investors and hedge funds own 82.01% of the company's stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.